Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Analysts at Alliance Global Partners cut their Q1 2025 earnings per share estimates for shares of Curaleaf in a research note issued on Tuesday, March 4th. Alliance Global Partners analyst A. Grey now anticipates that the company will earn ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Alliance Global Partners also issued estimates for Curaleaf’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.23) EPS.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.09. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%. The company had revenue of $331.05 million during the quarter, compared to analyst estimates of $331.87 million.
View Our Latest Analysis on CURLF
Curaleaf Stock Performance
Shares of CURLF opened at $1.04 on Thursday. The company has a market cap of $687.05 million, a price-to-earnings ratio of -3.59 and a beta of 0.57. Curaleaf has a 12 month low of $0.88 and a 12 month high of $6.40. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85. The business’s fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $2.17.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
- Five stocks we like better than Curaleaf
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- What Is WallStreetBets and What Stocks Are They Targeting?
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- The Most Important Warren Buffett Stock for Investors: His Own
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.